Lyell Immunopharma

About:

Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.

Website: https://lyell.com/

Top Investors: Bill & Melinda Gates Foundation, Mubadala, ARCH Venture Partners, Sahsen Ventures, Arrive

Description:

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.